drugset / Trial / NCT03642990

NR in Chemo-induced Peripheral Neuropathy

NCT03642990

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.

Timeline

Start
2019-11-08
Primary completion
2021-08-18
Completion
2022-02-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotinamide riboside Small molecule 1000 mg Oral